A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 ((225)Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract
| Authors: | Morris, M. J.; Wong, J. Y. C.; Nordquist, L.; Szmulewitz, R. Z.; Agarwal, N.; Attiyeh, E. F.; Max, S. I.; Divgi, C. R.; Patricia, D.; Cao, Y.; Li, X.; Yu, A.; Urtishak, K.; Lauring, J. D.; Sartor, O. |
| Abstract Title: | A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 ((225)Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC) |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557401257 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.5010 |
| Notes: | Meeting Abstract: 5010 -- Source: Wos |
